Search Results 1441-1450 of 19457 for Hemoglobin

1. A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   hemoglobin ≥ 8.0 g/dL;; Transfusion and / or growth factor support is permitted prior to assessment, but neutrophils, platelets, and hemoglobin must be ...

2. A Study to Evaluate Binimetinib in Combination with Encorafenib in Patients with Pancreatic Malignancies and a Somatic BRAFV600E Mutation - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL (obtained ≤ 14 days prior to registration). Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 14 days prior to ...

3. Study of Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer - Mayo Clinic

   Hemoglobin ≥ 8 g/dL. Note: Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial ...

4. A Study Comparing The Effectiveness And Safety Of Combining Three Versus Two Oral Treatments For The Initial Therapy Of Patients Who Have Newly Diagnosed Hypertension Of The Pulmonary Artery - Mayo Clinic

   Hemoglobin < 100 g/L assessed at screening. Known or suspected uncontrolled thyroid disease (hypo- or hyperthyroidism). Loss of vision in one or both eyes ...

5. Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer - Mayo Clinic

   Hemoglobin ≥ 85 mg/mL; Bilirubin ≤ 2 mg/dL; ALT and AST ≤ 5 X upper limit of normal; Amylase and lipase 1,5 X upper limit of normal; Serum creatinine ≤ 1.5 ...

6. Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors - Mayo Clinic

   Hemoglobin > 9 g/dL. Leukocytes ≥ 3,000/mcL. Absolute neutrophil count ≥ 1,500/mcL without the use of hematopoietic growth factors. Platelets ≥ 100,000 ...

7. Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination with Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer - Mayo Clinic

   Hemoglobin ≥9 g/dL; Platelets ≥100x109/L; Prothrombin time /International normalized ratio (INR) and partial thromboplastin time ≤1.3xULN (Subjects ...

8. Decitabine Dose-Tolerance in Surgically Resectable HPV-Negative Head and Neck Cancer - Mayo Clinic

   Hemoglobin ≥9.0 g/dL; Absolute neutrophil count (ANC) ≥1500/mm3; Platelet count ≥100,000/mm3; Total bilirubin ≤1.5 x ULN; Alanine aminotransferase (ALT) and ...

9. A Study to Evaluate the Veniti Vici™ Venous Stent System in Patients with a Chronic Iliofemoral Venous Outflow Obstruction - Mayo Clinic

   Uncorrected hemoglobin of ≤ 9 g/dL. Has an estimated glomerular filtration rate (eGFR) <30 mL/min. In patients with diabetes mellitus, eGFR <45 mL/min. Has ...

10. A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers - Mayo Clinic

    Participation eligibility · Hemoglobin ≥ 8 g/dL; · Absolute neutrophil count ≥ 1000/μL; · Platelet count ≥ 75,000/μL (≥ 30,000/μL if bone marrow plasma cells ...